Acute myeloid leukemia maturation lineage influences residual disease and relapse following differentiation therapy

Steven Ngo, Ethan P. Oxley, Margherita Ghisi, Maximilian M. Garwood, Mark D. McKenzie, Helen L. Mitchell, Peter Kanellakis, Olivia Susanto, Michael J. Hickey, Andrew C. Perkins, Benjamin T. Kile and Ross A. Dickins ()
Additional contact information
Steven Ngo: Australian Centre for Blood Diseases, Monash University
Ethan P. Oxley: Australian Centre for Blood Diseases, Monash University
Margherita Ghisi: Australian Centre for Blood Diseases, Monash University
Maximilian M. Garwood: Australian Centre for Blood Diseases, Monash University
Mark D. McKenzie: Walter and Eliza Hall Institute of Medical Research
Helen L. Mitchell: Australian Centre for Blood Diseases, Monash University
Peter Kanellakis: Baker Heart and Diabetes Institute
Olivia Susanto: Monash University Department of Medicine, Monash Medical Centre
Michael J. Hickey: Monash University Department of Medicine, Monash Medical Centre
Andrew C. Perkins: Australian Centre for Blood Diseases, Monash University
Benjamin T. Kile: Monash Biomedicine Discovery Institute, Monash University
Ross A. Dickins: Australian Centre for Blood Diseases, Monash University

Nature Communications, 2021, vol. 12, issue 1, 1-14

Abstract: Abstract Acute myeloid leukemia (AML) is a malignancy of immature progenitor cells. AML differentiation therapies trigger leukemia maturation and can induce remission, but relapse is prevalent and its cellular origin is unclear. Here we describe high resolution analysis of differentiation therapy response and relapse in a mouse AML model. Triggering leukemia differentiation in this model invariably produces two phenotypically distinct mature myeloid lineages in vivo. Leukemia-derived neutrophils dominate the initial wave of leukemia differentiation but clear rapidly and do not contribute to residual disease. In contrast, a therapy-induced population of mature AML-derived eosinophil-like cells persists during remission, often in extramedullary organs. Using genetic approaches we show that restricting therapy-induced leukemia maturation to the short-lived neutrophil lineage markedly reduces relapse rates and can yield cure. These results indicate that relapse can originate from therapy-resistant mature AML cells, and suggest differentiation therapy combined with targeted eradication of mature leukemia-derived lineages may improve disease outcome.

Date: 2021
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-021-26849-w Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-26849-w

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-021-26849-w

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().